The fully human immunoglobulin G4 monoclonal antibody drug tralokinumab (LEO Pharma A/S) was shown to be efficacious and safe for treating moderate-to-severe atopic dermatitis in adults, according to a Phase 2b study.
Mapping the human genome for chronic itch holds the potential to develop better targeted therapy for atopic dermatitis and psoriasis itch, according to the first study to describe the chronic itch transcriptome.
The Food and Drug Administration is in the process of evaluating scientific data on the safety of probiotics and postbiotics in cosmetics, said Linda Katz, M.D., director of the Office of Cosmetics and Color for the FDA.
In speaking at the 2018 AAD Summer Meeting in Chicago, one doctor recommends that dermatologists in training learn more about diagnosing and treating STDs due to increasing prevalence.
Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.
Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.
The science and techniques of biologics like nanofat continue to emerge. One presenter discussed yesterday how he uses this in facial procedures to treat fine lines, wrinkles, dyshcromia and areas of hyperpigmentation.
Expert provides insight into where he finds the greatest benefits.
There is increasing patient injury and legal action from cutaneous laser surgery, particularly when performed by non-physicians and especially when performed outside of traditional medical settings such as medical spas, a study shows.
Physicians writing in the Journal of the American Academy of Dermatology say that physicians should counter the proliferation of fake news on climate change.